Oncology Venture enters development deal with Cadila Pharmaceuticals on LiPlaCis® and its Drug Response Predictor
Hoersholm, Denmark, September 20th, 2016 – Oncology Venture Sweden AB (OV:ST) and Cadila Pharmaceuticals Ltd., Ahmedabad, State of Gujarat, India today announce the entering of a co-development agreement to develop the anticancer product LiPlaCis® in combination with its Drug Response Predictor – DRP™. The aim is to evaluate the LiPlaCis efficacy in several different indications and perform a randomized phase 3 trial as corner stone and part of the data package study for marketing approval by the FDA, EMA, CDSCO (Central Drugs Standard Control Organization of India). The mutual goal is to